AI Article Synopsis

  • SIRT6 is a member of the sirtuin family and plays various roles, including influencing immune response and cancer progression, which this study aimed to explore by linking SIRT6 expression to patient outcomes in solid tumors.
  • A meta-analysis was performed using data from PubMed and ISI Web of Science, focusing on the relationship between SIRT6 levels and clinicopathological features, ultimately leading to findings published in Cancer Research.
  • The study revealed that lower SIRT6 expression correlated with better overall and disease-free survival in patients with solid tumors, although its impact varied between cancer types, showing benefits in breast cancer but worse outcomes in gastrointestinal cancers.

Article Abstract

Purposes: In addition to its role in cellular progression and cancer, SIRT6, a member of nicotinamide adenine dinucleotide (NAD)-dependent class III deacylase sirtuin family, serves a variety of roles in the body's immune system. In this study, we sought to determine the relationship between the expression of SIRT6 and the clinicopathological outcomes of patients with solid tumours by conducting a meta-analysis of the available data.

Methods: The databases PubMed and ISI Web of Science were searched for relevant literature, and the results were presented here. Using Stata16.0, a meta-analysis was conducted to determine the impact of SIRT6 on clinicopathological characteristics and prognosis in malignancy patients. The results were published in the journal Cancer Research. The dataset from the Cancer Genome Atlas (TCGA) was used to investigate the prognostic significance of SIRT6 in various types of tumors.

Results: The inclusion and exclusion criteria were met by 15 studies. In patients with solid tumours, reduced SIRT6 expression was found to be related with improved overall survival (OS) (HR = 0.66, 95% CI = 0.45-0.97, P < 0.001) as well as improved disease-free survival (DFS) (HR = 0.48, 95% CI = 0.26-0.91, P < 0.001). Low SIRT6 expression was found to be associated with a better OS in breast cancer (HR = 0.49, 95% CI = 0.27-0.89, P = 0.179), but was found to be associated with a worse OS in gastrointestinal cancer (gastric cancer and colon cancer) (HR = 1.83, 95% CI = 1.20-2.79, P = 0.939) after subgroup analysis. In terms of clinicopathological characteristics, SIRT6 expression was found to be linked with distant metastasis (OR = 2.98, 95% CI = 1.59-5.57, P = 0.694). When the data from the TCGA dataset was compared to normal tissue, it was discovered that SIRT6 expression was significantly different in 11 different types of cancers. Meanwhile, reduced SIRT6 expression was shown to be associated with improved OS (P < 0.05), which was consistent with the findings of the meta-analysis. Aside from that, the expression of SIRT6 was found to be associated with both gender and clinical stage.

Conclusion: The overall data of the present meta-analysis indicated that low expression of SIRT6 may predict a favorable survival for patients with solid tumors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848894PMC
http://dx.doi.org/10.1186/s12935-022-02511-3DOI Listing

Publication Analysis

Top Keywords

patients solid
12
sirt6 clinicopathological
8
solid tumours
8
sirt6
6
clinicopathological prognostic
4
prognostic sirt6
4
patients
4
sirt6 patients
4
solid tumors
4
tumors meta-analysis
4

Similar Publications

Ringed esophagus: all that glitters is not gold.

Rev Gastroenterol Peru

January 2025

Universidad Peruana Cayetano Heredia, Lima, Perú.

We report the case of an elderly patient with progressive dysphagia to solids and later to liquids, and weight loss. The patient underwent an upper endoscopy, which showed multiple stenoses and trachealization. Biopsies were taken and a diagnosis of lymphocytic esophagitis was made.

View Article and Find Full Text PDF

Mechanical behavior of external root resorption cavities restored with different materials: a 3D-FEA study.

BMC Oral Health

January 2025

Faculty of Dentistry, Department of Endodontics, Ondokuz Mayis University, Samsun, Kurupelit, 55139, Turkey.

Background: The aim was to evaluate the stresses in teeth, with external root resorption (ERR) restored with different materials using finite element analysis (FEA).

Methods: In this study, a Micro-CT scan was conducted on a prepared maxillary central tooth. DICOM-compatible images obtained from the sections were converted into stereolithography format using Ctan software.

View Article and Find Full Text PDF

Objective: In clinical practice, diagnosing the benignity and malignancy of solid-component-predominant pulmonary nodules is challenging, especially when 3D consolidation-to-tumor ratio (CTR) ≥ 50%, as malignant ones are more invasive. This study aims to develop and validate an AI-driven radiomics prediction model for such nodules to enhance diagnostic accuracy.

Methods: Data of 2,591 pulmonary nodules from five medical centers (Zhengzhou People's Hospital, etc.

View Article and Find Full Text PDF

Purpose: Adrenal vascular tumors are mainly represented by adrenal cavernous hemangiomas (ACHs) and adrenal cystic lymphangiomas (ACLs). Their radiological features often overlap with malignant tumors, therefore ruling out malignancy becomes mandatory. We analyzed clinical, radiological, and histopathological data to identify specific characteristics of these tumors.

View Article and Find Full Text PDF

The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors.

Cell Biol Toxicol

January 2025

Department of Ultrasound, Shengjing Hospital of China Medical University, 110004, Shenyang, Liaoning, China.

Histone acetyltransferases p300 (E1A-associated protein p300) and CBP (CREB binding protein), collectively known as p300/CBP due to shared sequence and functional synergy, catalyze histone H3K27 acetylation and consequently induce gene transcription. p300/CBP over-expression or over-activity activates the transcription of oncogenes, leading to cancer cell growth, resistance to apoptosis, tumor initiation and development. The discovery of small molecule inhibitors targeting p300/CBP histone acetyltransferase activity, bromodomains, dual inhibitors of p300/CBP and BRD4 bromodomains, as well as proteolysis-targeted-chimaera p300/CBP protein degraders, marks significant progress in cancer therapeutics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!